THE ROLE OF STEM CELLS IN TISSUE REGENERATION AND PERSONALIZED MEDICINE

Abstract

Stem cell technology have revolutionised individualised medical care and regenerative medicine.  They heal and regenerate worn tissues as they naturally develop the capacity to replicate themselves and transform into other forms of specialised cells, and bring about patient-specific therapeutic actions with reduce rates of eliciting an immune reaction.  Here, the treatment potential and clinical outcomes and technological constraints of embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult stem cells particularly mesenchymal stem cells (MSCs) are examined in regenerative medicine in the broadest sense.  These data were assembled into nine large tables that contained 180 records of individual patients, including 12 intricate graphs, line, bar, pie, scatter, and hybrid plots depicting clinical trends, the changes in the immune response, and outcomes of CRISPR-enhanced treatment.  Findings indicated that the iPSCs possessed the greatest treatment efficacy whereby over 85 percent of the brain and cardiac tissue regeneration was attained besides the fact that they had minimal immune rejection when used in autologous settings.  ESCs retained their high level of pluripotency, though they were more immunogenic and more ethically questionable. MSCs, in their turn, had much weaker success in musculoskeletal tissue repair (about 70%) and could not differentiate so effectively.  It is clear that CRISPR-edited iPSCs did particularly well in preventing issues and even being better integrated with host tissues by a pleasing 30 percent.  Generally, the average percentage of recovered functional capacity was 70 with stem cell treatments in every application.  These findings demonstrate that iPSCs and CRISPR integration can be quite beneficial in clinical practice as the method entails production of safe, ethical, and personalised regenerative therapies.  The present research corroborates the further improvement of the protocol involving stem cells as a critically new aspect of the future of precision medicine although the issues of scalability, differentiation control, and regulatory schemes exist.